ATE422943T1 - Verfahren und verbindungen zur verstärkung der fybrozyten-bildung - Google Patents

Verfahren und verbindungen zur verstärkung der fybrozyten-bildung

Info

Publication number
ATE422943T1
ATE422943T1 AT03800146T AT03800146T ATE422943T1 AT E422943 T1 ATE422943 T1 AT E422943T1 AT 03800146 T AT03800146 T AT 03800146T AT 03800146 T AT03800146 T AT 03800146T AT E422943 T1 ATE422943 T1 AT E422943T1
Authority
AT
Austria
Prior art keywords
fybrocyte
enhancing
compounds
formation
methods
Prior art date
Application number
AT03800146T
Other languages
English (en)
Inventor
Richard Gomer
Darrell Pilling
Original Assignee
William Marsh Rice Univeristy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Marsh Rice Univeristy filed Critical William Marsh Rice Univeristy
Application granted granted Critical
Publication of ATE422943T1 publication Critical patent/ATE422943T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/729—Agar; Agarose; Agaropectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
AT03800146T 2002-12-23 2003-12-22 Verfahren und verbindungen zur verstärkung der fybrozyten-bildung ATE422943T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43602702P 2002-12-23 2002-12-23
US43604602P 2002-12-23 2002-12-23
US51577603P 2003-10-30 2003-10-30
US51946703P 2003-11-12 2003-11-12
US52517503P 2003-11-26 2003-11-26

Publications (1)

Publication Number Publication Date
ATE422943T1 true ATE422943T1 (de) 2009-03-15

Family

ID=32686361

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03814319T ATE500839T1 (de) 2002-12-23 2003-12-22 Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung
AT03800146T ATE422943T1 (de) 2002-12-23 2003-12-22 Verfahren und verbindungen zur verstärkung der fybrozyten-bildung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03814319T ATE500839T1 (de) 2002-12-23 2003-12-22 Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung

Country Status (13)

Country Link
US (3) US7935682B2 (de)
EP (3) EP1596880B1 (de)
JP (4) JP4819364B2 (de)
AT (2) ATE500839T1 (de)
AU (2) AU2003299873A1 (de)
CA (2) CA2509392A1 (de)
CY (1) CY1111536T1 (de)
DE (2) DE60326273D1 (de)
DK (1) DK1596880T3 (de)
ES (1) ES2318195T3 (de)
IL (1) IL169258A0 (de)
PT (1) PT1596880E (de)
WO (2) WO2004058292A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
WO2007094776A1 (en) * 2006-02-15 2007-08-23 William Marsh Rice University Compositions and methods for suppressing fibrocyte differentiation
JP4819364B2 (ja) 2002-12-23 2011-11-24 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物
US20100297074A1 (en) * 2002-12-23 2010-11-25 Richard Hans Gomer Wound healing compositions, systems, and methods
US20060264367A1 (en) * 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US8642307B2 (en) * 2006-05-25 2014-02-04 Nalge Nunc International Corporation Cell culture surface chemistries
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8114608B2 (en) * 2006-11-30 2012-02-14 University Of Virginia Patent Foundation Methods for treating and diagnosing fibrotic and fibroproliferative diseases
US8247370B2 (en) 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) * 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use
US20100190963A1 (en) * 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
US10702583B2 (en) 2009-03-11 2020-07-07 Promedior, Inc. Treatment methods for autoimmune disorders
JP5797565B2 (ja) 2009-03-11 2015-10-21 プロメディオール， インコーポレイテッド 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅ ｄｉｓｏｒｄｅｒ）に対する処置および診断方法
US20100266643A1 (en) * 2009-04-01 2010-10-21 Willett W Scott Pulmonary and nasal delivery of serum amyloid p
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
US8329659B2 (en) * 2009-06-17 2012-12-11 Promedior, Inc. SAP variants and their use
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
EP2571903B1 (de) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulusreaktive polymere zur aufreinigung von biomolekülen
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
EP2790690A4 (de) * 2011-12-14 2015-08-12 Texas A & M Univ Sys Zusammensetzungen und verfahren zur verwaltung neutrophiler bewegungen unter verwendung des serum-amyloids p (sap)
ES2728446T3 (es) * 2011-12-21 2019-10-24 Promedior Inc Proteínas de fusión de P-anticuerpos de amiloide sérico
JP6104286B2 (ja) * 2013-01-21 2017-03-29 三菱電機株式会社 電気機器識別システム、電気機器、及び、電気機器識別方法
US10562974B2 (en) 2013-03-13 2020-02-18 University Of Kentucky Research Foundation Methods of administering IgG1 antibodies and methods of suppressing angiogenesis
JP6601707B2 (ja) * 2015-02-15 2019-11-06 国立大学法人金沢大学 線維化判定方法
BR112018016004A2 (pt) * 2016-02-08 2018-12-18 Univ Hackensack Medical Center composições e métodos para tratar feridas crônicas
JP6780600B2 (ja) * 2017-07-28 2020-11-04 株式会社デンソー 内燃機関制御システム

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1562244A (en) * 1976-11-11 1980-03-05 Lock P M Wound dressing materials
GB1594389A (en) * 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
DE2725261C2 (de) 1977-06-03 1986-10-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Transparentes Flüssigkeitsverbandmaterial, seine Herstellung und Verwendung
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
DE3853219T2 (de) * 1987-11-20 1995-06-29 Kanegafuchi Chemical Ind Methode zur Entfernung von Serum-Amyloid-Protein.
US7070994B2 (en) * 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5092876A (en) * 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US6054121A (en) * 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
US5804446A (en) * 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
ATE226829T1 (de) * 1996-01-25 2002-11-15 Profylakse Aps Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
CN1307590A (zh) 1998-02-17 2001-08-08 米德列斯公司 用fc受体配基治疗和诊断巨噬细胞介导的疾病
ES2220257T1 (es) * 1998-03-11 2004-12-16 Kabushiki Kaisha Soken Agentes normalizadores para la piel.
JPH11319542A (ja) * 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6600019B2 (en) * 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
EP1267795A1 (de) * 2000-03-30 2003-01-02 Brennen Medical Inc. Antimikrobielle und immunstimulierende zusammensetzung
US20040068095A1 (en) * 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
CA2449466A1 (en) * 2001-06-04 2002-12-12 The Picower Institute For Medical Research Peripheral blood fibrocytes differentiation pathway and migration to wound sites
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) * 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
JP4819364B2 (ja) 2002-12-23 2011-11-24 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物
SG173322A1 (en) 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
WO2006002438A2 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor i (cd64)

Also Published As

Publication number Publication date
JP4819364B2 (ja) 2011-11-24
WO2004058292A3 (en) 2004-10-28
CY1111536T1 (el) 2015-10-07
US7666432B2 (en) 2010-02-23
AU2003300266A2 (en) 2008-02-21
EP2017617A1 (de) 2009-01-21
PT1596880E (pt) 2011-06-06
ATE500839T1 (de) 2011-03-15
EP1576368B1 (de) 2009-02-18
DE60326273D1 (de) 2009-04-02
AU2003300266B2 (en) 2009-10-08
ES2318195T3 (es) 2009-05-01
WO2004058292A2 (en) 2004-07-15
US20110311554A1 (en) 2011-12-22
US8187599B2 (en) 2012-05-29
EP1596880A2 (de) 2005-11-23
JP4922560B2 (ja) 2012-04-25
AU2003300266A1 (en) 2004-07-22
CA2509241C (en) 2013-07-30
DE60336347D1 (de) 2011-04-21
DK1596880T3 (da) 2011-06-14
AU2003299873A1 (en) 2004-07-22
EP1596880B1 (de) 2011-03-09
JP2011016824A (ja) 2011-01-27
US20050238620A1 (en) 2005-10-27
WO2004058292A8 (en) 2005-08-25
AU2003299873A2 (en) 2008-02-28
WO2004059318A3 (en) 2005-05-06
CA2509392A1 (en) 2004-07-15
JP2006511586A (ja) 2006-04-06
JP2014141512A (ja) 2014-08-07
JP2006514654A (ja) 2006-05-11
US20060002938A1 (en) 2006-01-05
EP1576368A2 (de) 2005-09-21
IL169258A0 (en) 2007-07-04
CA2509241A1 (en) 2004-07-15
WO2004059318A2 (en) 2004-07-15
US7935682B2 (en) 2011-05-03

Similar Documents

Publication Publication Date Title
ATE500839T1 (de) Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung
ATE409037T1 (de) Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE318820T1 (de) Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren.
ATE345130T1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
EP2015723A4 (de) Integriertes wundverbandsystem
DE60100851D1 (de) Piperidin verbindung zur behandlung von psoriasis
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE348631T1 (de) Verwendung von plasminogen zur heilung von zerbrochenen trommelfellen
ATE395022T1 (de) Zusammensetzung und verfahren zur beschleunigung von wunden- und brandheilung
DE69902154D1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
DE60212613D1 (de) Doxycyclin zur behandlung von akne
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
DE60220043D1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE60040523D1 (de) Methoden zur behandlung von nägeln
EP1409015A4 (de) Verfahren zur behandlung oder vorbeugung von hauterkrangungen unter verwendung von cd2-bindungsagenzien
ATE278441T1 (de) Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind
DE60237039D1 (de) Verfahren zur behandlung von rosacea und telangiectasia
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE602007010459D1 (de) Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie
DE602004023100D1 (de) Verbindungen und verfahren zur behandlung von dyslipidemie
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
EE200300580A (et) Meetod ja inertse absorbeeriva savi kasutamine segu töötlemiseks ning saadus
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties